TWiV considers lessons learned from COVID-19 about emergency drug use during a pandemic, and selection of AAV capsids to produce vectors that efficiently deliver genes to muscle cells.
TWiV 697: The sky is NOT falling
- December 24, 2020
- Tagged as: aav, ACE2 receptor, coronavirus, COVID-19, mutation, Orf8, pandemic, SARS-CoV-2, spike protein, transmission, UK variant, variant of concern, viral, virology, virus, viruses, VOC202012/01
TWiV reviews the latest data on the UK variant of SARS-CoV-2, including some properties of the variant and why it is being closely studied, development of liver cancer in a participant in a adenovirus-associated virus gene therapy trial, and answers to listener questions.
At the University of Zürich, Vincent speaks with virologists Cornel Fraeful, Urs Greber, and Silke Stertz about their careers and their work on AAV2, adenovirus entry, and influenza virus.
From ASV 2017 in Madison, Wisconsin, the complete TWiV team speaks with Mavis Agbandje-McKenna about her career and her work solving virus structures by x-ray crystallography and cryo-electron microscopy.
Vincent speaks with Katherine High about her career and her work on using viral gene therapy to treat inherited disorders.
The sternutating TWiVers discuss preventing infection of cells and animals by a soluble CD4-CCR5 molecule that binds to HIV-1 virus particles.
Vincent, Alan and Kathy review novel approaches to preventing influenza virus infection.
Welkin joins the TWiV team for a discussion of HIV prophylaxis using vectored antibodies, and the influenza H5N1 virus studies in ferrets that were not redacted.